Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Tavapadon
Другие языки:

    Tavapadon

    Подписчиков: 0, рейтинг: 0
    Tavapadon
    Tavapadon.svg
    Clinical data
    Other names CVL-751; PF-6649751; PF-06649751
    Identifiers
    • 1,5-dimethyl-6-[2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]oxyphenyl]pyrimidine-2,4-dione
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    ChEMBL
    Chemical and physical data
    Formula C19H16F3N3O3
    Molar mass 391.350 g·mol−1
    3D model (JSmol)
    • CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C
    • InChI=1S/C19H16F3N3O3/c1-10-9-12(28-17-14(19(20,21)22)5-4-8-23-17)6-7-13(10)15-11(2)16(26)24-18(27)25(15)3/h4-9H,1-3H3,(H,24,26,27)
    • Key:AKQXQLUNFKDZBN-UHFFFAOYSA-N

    Tavapadon (developmental code names CVL-751, PF-6649751, PF-06649751) is a dopamine receptor agonist which is under development by Pfizer and Cerevel Therapeutics for the treatment of Parkinson's disease. It acts as a selective partial agonist of the dopamine D1 (Ki = 8.54 nM) and D5 receptors. It also shows biased agonism for Gs-coupled signaling. As of July 2021, tavapadon is in phase 3 clinical trials for Parkinson's disease.

    See also


    Новое сообщение